Clinical Study

Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival

3 May 2016
Nicoletta Biglia, Paola Sgandurra, Valentina Elisabetta Bounous, Furio Maggiorotto, Eleonora Piva, Emanuele Pivetta, Riccardo Ponzone, Barbara Pasini

Objectives: To compare clinical–pathological characteristics and outcome between sporadic ovarian cancer and ovarian cancer in patents with hereditary breast and ovarian cancer syndrome (HBOC).

Methods: Twenty-four patients with ovarian cancer treated between 2000 and 2009 who tested positive for BRCA1/2 mutation (BRCA) and a control group of 64 age-matched patients with no family history of breast/ovarian cancer (controls) were enrolled. Clinical–pathological characteristics, surgical outcome, overall (OS), and progression-free survival (PFS) were compared between the two groups.

Results: The high-grade serous histotype was more represented in BRCA than in controls (70.8% versus 53.1%) (p > 0.05). BRCA cancers were more frequently diagnosed at stage II than controls (20.83% versus 4.69%) (p = 0.024). Radical primary surgery was performed in 70% of women in both groups, with no difference in debulking results. In patients undergoing surgery after neoadjuvant chemotherapy, in all BRCA patients, optimal cytoreduction was achieved (versus 70% of the controls). PFS was significantly longer for BRCA patients compared to controls (60 months versus 22 months; p = 0.039). No significant difference was observed in OS between BRCA patients and controls.

Conclusions: At a median follow-up time of 46 months, BRCA patients have a better prognosis than controls in terms of PFS. Higher chemosensitivity of BRCA tumours was observed.

Article metrics: 3546 views

Related Articles

Sharada Mailankody, Manikandan Dhanushkodi, Trivadi S Ganesan, Venkatraman Radhakrishnan, Vasanth Christopher, Selvaluxmy Ganesharajah, Tenali Gnana Sagar